SMCypI C31

SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC50 of 0.1 μM) . SMCypI C31 shows pangenotype anti-HCV activity with EC50s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction[1][2].

Product Specifications

CAS Number

[2649904-85-6]

UNSPSC

12352005

Target

Cyclophilin; HCV

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/smcypi-c31.html

Solubility

10 mM in DMSO

Smiles

O=C(NC(C1=CC=CC=C1)C(N2C(C3=CC=CC=C3SC)CCC2)=O)NCC4=CC=C(N)C=C4

Molecular Formula

C27H30N4O2S

Molecular Weight

474.62

References & Citations

[1]Quentin Nevers, et al. Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity. Antimicrob Agents Chemother. 2018 Jun 26;62 (7) :e00126-18.|[2]Abdelhakim Ahmed-Belkacem, et al. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat Commun. 2016 Sep 22;7:12777.